Medigene (FSE: MDG1) is a publicly listed, immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors.
TCR-T expertise is the foundation for our integrated proprietary End-to-End Platform which includes multiple TCR generation and optimization technologies as well as product enhancement technologies.
tCR-T Therapies face challenges in delivering optimal patient outcomes in solid tumors
Medigene´s solutions to address challenges of optimizing tcr-t therapy outcomes in solid tumors
TCR: T cell receptor; TME: tumor microenvinronment; CSP: costimulatory switch protein
Medigene’s strategy is to develop its therapies towards clinical proof-of-concept with the ultimate aim of advancing its technologies into development against solid cancers. In addition, the company offers selected partners the opportunity to discover and develop additional therapies by accessing Medigene’s proprietary End-to-End Platform that includes optimization technologies (like our Allo-HLA priming) and enhancement technologies (like our PD1-41BB and CD40L-CD28 costimulatory switch proteins).